D
rugmakers around the world are scrambling to develop a COVID-19 shot, and Emergent BioSolutions has already signed on to help produce doses for some major players. Now, the Gaithersburg, Maryland-based biopharma has scored a contract update to deploy future vaccine doses for a wholly different kind of health crisis.
Image: Emergent launched a phase 3 trial on NuThrax in March last year; that study is on track to finish by the year's end. (FiercePharma) - https://www.fiercepharma.com